2-phenyl-2-(pyrimidin-2-yl)ethanamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-phenyl-2-(pyrimidin-2-yl)ethanamine
• 英文别名: 2-phenyl-2-pyrimidin-2-ylethanamine
• 化学式: C₁₂H₁₃N₃
• 分子量: 199.255
• InChiKey: BOYPPDSBHYMDLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  51.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,4-二氯喹唑啉 、 2-phenyl-2-(pyrimidin-2-yl)ethanamine 在 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 以55%的产率得到2-chloro-N-(2-phenyl-2-(pyrimidin-2-yl)ethyl)quinazolin-4-amine
  参考文献：
  名称：

  [EN] HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS
  [FR] COMPOSÉS HÉTÉROCYCLIQUES EN TANT QUE MODULATEURS DU TRANSPORT D'AMINES BIOGÈNES

  摘要：

  本公开涉及抑制生物胺转运体多巴胺转运体（DAT）、5-羟色胺转运体（SERT）和去甲肾上腺素转运体（NET）的某些融合双环杂环生物胺衍生物的化合物。本公开的化合物是多巴胺（DA）、5-羟色胺（5-HT）和去甲肾上腺素（NE）的重摄取的有效抑制剂，具有完全或部分最大效力。在抑制所有三种生物胺的重摄取中具有部分最大效力的化合物在此被称为部分三重摄取抑制剂（PTRIs）。本公开的化合物可用于治疗抑郁症、疼痛、物质滥用、物质滥用复发以及对可卡因、甲基苯丙胺、尼古丁和酒精等物质的成瘾。本摘要旨在作为在特定领域进行搜索的扫描工具，并不意在限制本发明。

  公开号：

  WO2016090296A1

文献信息

• HETEROCYCLIC COMPOUNDS AS BIOGENIC AMINE TRANSPORT MODULATORS
  申请人：ANANTHAN Subramaniam

  公开号：US20160159809A1

  公开（公告）日：2016-06-09

  The present disclosure relates to certain amine derivatives of fused bicyclic heterocycles that inhibit the amine reuptake function of the biogenic amine transporters, dopamine transporter (DAT), serotonin transporter (SERT) and norepinephrine transporter (NET). Compounds of the present disclosure are potent inhibitors of the reuptake of dopamine (DA), serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) with full or partial maximal efficacy. The compounds with partial maximal efficacy in inhibiting reuptake of all three biogenic amines are herein referred to as partial triple uptake inhibitors (PTRIs). Compounds of the present disclosure are useful for treating depression, pain and substance abuse and relapse to substance abuse and addiction to substances such as cocaine, methamphetamine, nicotine and alcohol. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

  本公开涉及融合的双环杂环胺衍生物，其抑制生物胺转运体的胺重摄取功能，包括多巴胺转运体（DAT）、血清素转运体（SERT）和去甲肾上腺素转运体（NET）。本公开的化合物是多巴胺（DA）、血清素（5-羟色胺，5-HT）和去甲肾上腺素（NE）重摄取的有效抑制剂，具有完全或部分的最大功效。部分三重重摄取抑制剂（PTRIs）指部分最大功效抑制三种生物胺的重摄取的化合物。本公开的化合物可用于治疗抑郁症、疼痛和物质滥用以及物质滥用和对可卡因、甲基安非他明、尼古丁和酒精等物质成瘾的复发。该摘要旨在作为特定领域搜索的扫描工具，不旨在限制本发明。
• CXER4 ANTAGONISTS INCLUDING DIAZINE AND TRIAZINE STRUCTURES FOR THE TREATMENT OF MEDICAL DISORDERS
  申请人：EMORY UNIVERSITY

  公开号：EP2041067A2

  公开（公告）日：2009-04-01
• CXCR4 Antagonists Including Diazine And Triazine Structures For The Treatment Of Medical Disorders
  申请人：Liotta Dennis C.

  公开号：US20090099194A1

  公开（公告）日：2009-04-16

  The invention provides compounds, pharmaceutical compositions and methods of use of certain compounds that are antagonists of the chemokine CXCR4 receptor for the treatment of proliferative conditions mediated by CXCR4 receptors or for the treatment of viral infections. The compounds provided interfere with the binding of SDF 1 to the receptor. These compounds are particularly useful for treating or reducing the severity of hyperproliferative diseases by inhibiting metastasis, or for reducing entry of HIV in to a cell while not reducing the capacity of the stem cells to proliferate. The compounds may be useful for long term treatment regimes.
• CXCR4 ANTAGONISTS FOR IMAGING OF CANCER AND INFLAMMATORY DISORDERS
  申请人：Shim Hyunsuk

  公开号：US20120294803A1

  公开（公告）日：2012-11-22

  The invention provides radiolabeled CXCR4 antagonists, compositions and methods of use for imaging of chemokine CXCR4 receptors and biological conditions associated with the expression of CXCR4 receptors, including cancer, metastasis, and inflammatory disorders.
• US8080659B2
  申请人：——

  公开号：US8080659B2

  公开（公告）日：2011-12-20